Seegene, a leading molecular diagnostics company, has announced a collaboration with Werfen, a global healthcare company, to create qPCR assays for Spain and Portugal. The partnership aims to provide accurate and reliable diagnostic solutions for infectious diseases, including COVID-19.
qPCR (quantitative polymerase chain reaction) is a widely used molecular diagnostic technique that detects and quantifies DNA or RNA in a sample. It is a highly sensitive and specific method that can detect even small amounts of genetic material, making it ideal for detecting infectious agents such as viruses and bacteria.
Seegene is known for its innovative multiplex PCR technology, which allows the simultaneous detection of multiple pathogens in a single test. The company has developed a range of qPCR assays for various infectious diseases, including COVID-19, influenza, and respiratory syncytial virus (RSV).
Werfen, on the other hand, is a global healthcare company that specializes in in vitro diagnostics (IVD) and critical care testing. The company offers a wide range of diagnostic solutions for various medical conditions, including infectious diseases, cardiovascular disorders, and cancer.
The collaboration between Seegene and Werfen aims to leverage their respective strengths to develop high-quality qPCR assays for the Spanish and Portuguese markets. The partnership will combine Seegene’s expertise in multiplex PCR technology with Werfen’s extensive distribution network and local market knowledge.
The qPCR assays developed through this collaboration will be designed to meet the specific needs of the Spanish and Portuguese healthcare systems. They will be optimized for use with local sample types and will be validated according to local regulatory requirements.
The COVID-19 pandemic has highlighted the importance of accurate and reliable diagnostic testing in controlling the spread of infectious diseases. The collaboration between Seegene and Werfen is expected to contribute to the fight against COVID-19 by providing high-quality diagnostic solutions for the Spanish and Portuguese markets.
In addition to COVID-19, the qPCR assays developed through this collaboration will also be useful for detecting other infectious agents, such as influenza, RSV, and tuberculosis. They will enable healthcare professionals to quickly and accurately diagnose these diseases, allowing for timely treatment and management.
Overall, the collaboration between Seegene and Werfen is a significant development in the field of molecular diagnostics. It demonstrates the importance of partnerships and collaborations in developing innovative diagnostic solutions that can improve patient outcomes and contribute to public health.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- EVM Finance. Unified Interface for Decentralized Finance. Access Here.
- Quantum Media Group. IR/PR Amplified. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...